低剂量阿司匹林对ASCEND随机对照试验中糖尿病患者尿11-脱氢血栓烷B2的影响
ASCEND随机双盲试验中,每日阿司匹林100 mg与安慰剂对比,在无心血管疾病史的糖尿病患者中通过尿11-脱氢血栓烷B2(U-TXM)评估抑制效果。随机样本中阿司匹林组U-TXM较安慰剂组低71%(95%CI 64-76%),依从者中低72%(95%CI 69-75%),总体77%达到有效抑制。结论认为每日阿司匹林显著降低糖尿病患者U-TXM,包括服药后12-24小时。
要点
- 随机样本中阿司匹林组U-TXM较安慰剂组低71%(95%CI 64-76%)。
- 依从者中阿司匹林组U-TXM较安慰剂组低72%(95%CI 69-75%),77%达到有效抑制。
- 服药后超过12小时采样者中,阿司匹林组U-TXM较安慰剂组低72%(95%CI 67-77%),70%达到有效抑制。
核心结论
- 每日阿司匹林显著降低糖尿病患者的U-TXM,包括服药后12-24小时。
研究设计与样本
- ASCEND随机双盲试验,每日阿司匹林100 mg与安慰剂对比,对象为无心血管疾病史的糖尿病患者。
- 随机选取152名参与者(阿司匹林组76名,安慰剂组74名),另选198名依从研究药物者(阿司匹林组93名,安慰剂组105名),并尽量使末次服药至采样间隔为12-24小时。
- U-TXM采用竞争性ELISA法测定,样本在随机化后平均2年邮寄,采样时记录距末次服药时间。
主要发现
- 随机样本中,阿司匹林组U-TXM较安慰剂组低71%(95%CI 64-76%)。
- 依从者中,阿司匹林组U-TXM较安慰剂组低72%(95%CI 69-75%),总体77%达到有效抑制(U-TXM<1500 pg/mg肌酐)。
- 末次服药超过12小时采样者中,阿司匹林组U-TXM较安慰剂组低72%(95%CI 67-77%),70%达到有效抑制。
关键数值与推荐
- 有效抑制定义为U-TXM<1500 pg/mg肌酐。
- 随机样本中阿司匹林组U-TXM较安慰剂组低71%(95%CI 64-76%)。
- 依从者中阿司匹林组U-TXM较安慰剂组低72%(95%CI 69-75%),77%达到有效抑制。
- 末次服药超过12小时采样者中阿司匹林组U-TXM较安慰剂组低72%(95%CI 67-77%),70%达到有效抑制。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aspirin is widely used for cardioprotection with its antiplatelet effects due to the blocking of thromboxane A2 production. However, it has been suggested that platelet abnormalities in those with diabetes prevent adequate suppression with once daily aspirin. METHODS: In the ASCEND randomized double-blind trial of aspirin 100 mg once daily versus placebo in participants with diabetes but no history of cardiovascular disease, suppression was assessed by measuring 11-dehydro-thromboxane B2 excretion in urine (U-TXM) in a randomly selected sample of 152 participants (76 aspirin arm, 74 placebo arm), plus 198 (93 aspirin arm, 105 placebo arm) adherent to study drugs and selected to maximize the numbers ingesting their last tablet 12-24 h before urine sampling. U-TXM was assayed using a competitive ELISA assay in samples mailed a mean of 2 years after randomization, with time since taking last aspirin/placebo tablet recorded at the time of sample provision. Effective suppression (U-TXM < 1500 pg/mg creatinine) and percentage reductions in U-TXM by aspirin allocation were compared. RESULTS: In the random sample, U-TXM was 71% (95% CI 64-76%) lower among aspirin vs placebo-allocated participants. Among adherent participants in the aspirin arm, U-TXM was 72% (95% CI 69-75%) lower than in the placebo arm and 77% achieved effective suppression overall. Suppression was similar among those who ingested their last tablet more than 12 h before urine sampling with levels in the aspirin arm 72% (95% CI 67-77%) lower than in the placebo arm and 70% achieving effective suppression. CONCLUSIONS: Daily aspirin significantly reduces U-TXM in participants with diabetes, including at 12-24 h after ingestion. TRIAL REGISTRATION: ISRCTN ISRCTN60635500. Registered on 1 Sept 2005; ClinicalTrials.gov NCT00135226. Registered on 24 Aug 2005.
引用
- Parish S, Buck G, Aung T, et al. Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial. Trials. 2023. PMID: 36871000. doi:10.1186/s13063-023-07198-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。